HGSI

Hassan Sharif is the CEO of Human Genome Sciences. To contact Hassan Sharif email at [email protected].

The decision makers in HGSI are Bill Hannon, Cobus Vermaak, Golden Unyeowaji, etc. Click to Find HGSI decision makers emails.

Human Genome Sciences (HGS) specializes in developing innovative biopharmaceutical products, particularly monoclonal antibodies (mAbs). Our focus is on creating therapies that target specific diseases, leveraging our advanced research and development capabilities to bring cutting-edge treatments to market.

HGS primarily serves the healthcare and pharmaceutical industries. Our solutions are designed to address unmet medical needs across various therapeutic areas, including oncology, autoimmune diseases, and infectious diseases. We collaborate with healthcare providers and research institutions to ensure our products meet the highest standards of efficacy and safety.

HGS boasts world-class research and development facilities equipped with state-of-the-art technology. Our R&D team is dedicated to advancing the science of biopharmaceuticals, focusing on the discovery and development of novel therapies. We employ a rigorous scientific approach, including preclinical and clinical trials, to ensure our products are both effective and safe for patients.

HGS has recently received approval for several of its biopharmaceutical products, including innovative monoclonal antibody therapies that target specific diseases. These approvals are a testament to our commitment to developing effective treatments and our adherence to regulatory standards. For detailed information on specific products and their indications, please refer to our product pipeline on our website.

HGS prioritizes quality and safety at every stage of the product lifecycle. We adhere to stringent regulatory guidelines and industry best practices in our manufacturing processes. Our facilities are equipped with advanced quality control systems, and we conduct thorough testing and validation of our products to ensure they meet the highest safety and efficacy standards before reaching the market.

HGS is open to collaboration with other pharmaceutical companies, research institutions, and healthcare providers. We believe that partnerships can accelerate the development of innovative therapies. Interested parties can reach out to our business development team through our website to explore potential collaboration opportunities in research, development, and commercialization of biopharmaceutical products.